Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.

SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...

Boehringer Ingelheim and Simcere are developing SIM0709, a pre-clinical bispecific antibody, for treating inflammatory bowel disease (IBD).

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

LONDON - About 5% of the world’s population, including an estimated 3.1 million adults in the U.S., suffer from inflammatory bowel disease (IBD) – the umbrella term for Crohn’s disease and ulcerative ...

A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a ...

Inflammatory bowel disease (IBD) therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not escalate IBD flares, with prior vaccination for COVID-19 helping ...

IBD treatment usually focuses on medication, but diet clearly influences symptoms and inflammation. Here’s why an extreme elimination diet like carnivore is getting attention—and why researchers are ...